DK2041270T3 - Fremstilling af glycoproteiner - Google Patents

Fremstilling af glycoproteiner

Info

Publication number
DK2041270T3
DK2041270T3 DK07796784T DK07796784T DK2041270T3 DK 2041270 T3 DK2041270 T3 DK 2041270T3 DK 07796784 T DK07796784 T DK 07796784T DK 07796784 T DK07796784 T DK 07796784T DK 2041270 T3 DK2041270 T3 DK 2041270T3
Authority
DK
Denmark
Prior art keywords
glycoproteins
preparation
Prior art date
Application number
DK07796784T
Other languages
English (en)
Inventor
Daniel R Lasko
Stephan M Koza
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2041270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK2041270T3 publication Critical patent/DK2041270T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07796784T 2006-07-13 2007-07-11 Fremstilling af glycoproteiner DK2041270T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13
PCT/US2007/015767 WO2008008360A1 (en) 2006-07-13 2007-07-11 Production of glycoproteins

Publications (1)

Publication Number Publication Date
DK2041270T3 true DK2041270T3 (da) 2014-01-27

Family

ID=38645762

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07796784T DK2041270T3 (da) 2006-07-13 2007-07-11 Fremstilling af glycoproteiner
DK17179340.9T DK3255141T3 (da) 2006-07-13 2007-07-11 Fremstilling af antistoffer med forbedret glycosyleringsmønster
DK12164058.5T DK2495307T5 (da) 2006-07-13 2007-07-11 Fremstilling af koagulationsfaktor IX med forbedret glycosyleringsmønster

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK17179340.9T DK3255141T3 (da) 2006-07-13 2007-07-11 Fremstilling af antistoffer med forbedret glycosyleringsmønster
DK12164058.5T DK2495307T5 (da) 2006-07-13 2007-07-11 Fremstilling af koagulationsfaktor IX med forbedret glycosyleringsmønster

Country Status (23)

Country Link
US (1) US8129145B2 (da)
EP (3) EP3255141B1 (da)
JP (1) JP5401310B2 (da)
KR (1) KR101495549B1 (da)
CN (2) CN104878064A (da)
AR (1) AR061976A1 (da)
AU (1) AU2007272957B2 (da)
BR (1) BRPI0714212B8 (da)
CA (1) CA2657248C (da)
DK (3) DK2041270T3 (da)
ES (2) ES2440487T3 (da)
HK (1) HK1214307A1 (da)
HU (1) HUE039128T2 (da)
IL (1) IL196252A (da)
MX (1) MX2009000349A (da)
PE (1) PE20081194A1 (da)
PL (2) PL2495307T3 (da)
PT (2) PT2495307T (da)
RU (1) RU2463345C2 (da)
SI (1) SI2495307T1 (da)
TR (1) TR201807021T4 (da)
TW (1) TW200812577A (da)
WO (1) WO2008008360A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
CA2679941C (en) * 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
EP3009447B1 (en) * 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
LT2563906T (lt) 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9631216B2 (en) 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
CN103827134A (zh) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
EP3036254A1 (en) * 2013-08-20 2016-06-29 LEK Pharmaceuticals d.d. Cell culture medium and process for controlling -amidation and/or c-terminal amino acid cleavage of polypeptides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3110941A4 (en) 2014-02-25 2017-10-18 Dr. Reddy's Laboratories Ltd. Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
RS59881B1 (sr) * 2014-02-27 2020-03-31 Hoffmann La Roche Modulacija ćelijskog rasta i glikozilacije u rekombinantnoj proizvodnji glikoproteina
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
WO2016196621A1 (en) 2015-06-01 2016-12-08 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
EP3625329A1 (en) 2017-05-17 2020-03-25 Octapharma AG Method for the production of a recombinant target protein
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CN113015805B (zh) 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
EP4196598A2 (en) * 2020-08-14 2023-06-21 Bristol-Myers Squibb Company Method of making protein
US20240150723A1 (en) * 2021-03-23 2024-05-09 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production
CN119371539A (zh) * 2024-12-05 2025-01-28 齐鲁制药有限公司 用于生产抗cd38抗体的方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) * 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU2455199A (en) 1998-01-12 1999-07-26 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
WO1999043839A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
DK1266006T3 (da) 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
CA2628340A1 (en) 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner

Also Published As

Publication number Publication date
AU2007272957B2 (en) 2014-05-01
PE20081194A1 (es) 2008-09-22
KR101495549B1 (ko) 2015-02-25
DK2495307T5 (da) 2018-07-16
ES2668212T9 (es) 2018-05-30
CA2657248A1 (en) 2008-01-17
PT2495307T (pt) 2018-05-10
PT2041270E (pt) 2013-12-27
RU2463345C2 (ru) 2012-10-10
PL2041270T3 (pl) 2014-04-30
JP5401310B2 (ja) 2014-01-29
WO2008008360A1 (en) 2008-01-17
TW200812577A (en) 2008-03-16
IL196252A0 (en) 2011-08-01
EP3255141A1 (en) 2017-12-13
EP2041270B1 (en) 2013-11-20
MX2009000349A (es) 2009-03-09
EP3255141B1 (en) 2021-12-01
US20080081356A1 (en) 2008-04-03
AR061976A1 (es) 2008-08-10
EP2495307A1 (en) 2012-09-05
IL196252A (en) 2016-02-29
SI2495307T1 (en) 2018-05-31
JP2009543550A (ja) 2009-12-10
BRPI0714212B8 (pt) 2021-05-25
CN104878064A (zh) 2015-09-02
US8129145B2 (en) 2012-03-06
KR20090029841A (ko) 2009-03-23
EP2495307B1 (en) 2018-02-21
PL2495307T3 (pl) 2018-07-31
ES2440487T3 (es) 2014-01-29
ES2668212T3 (es) 2018-05-17
EP2041270A1 (en) 2009-04-01
HK1214307A1 (zh) 2016-07-22
CN101541950A (zh) 2009-09-23
DK2495307T3 (da) 2018-05-07
BRPI0714212B1 (pt) 2021-01-19
RU2008152449A (ru) 2010-08-20
HUE039128T2 (hu) 2018-12-28
BRPI0714212A2 (pt) 2013-03-26
EP2495307B9 (en) 2018-05-02
TR201807021T4 (tr) 2018-06-21
CA2657248C (en) 2018-10-30
DK3255141T3 (da) 2022-01-31
AU2007272957A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
DK1981859T3 (da) Fremstilling af delmopinol
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK1877568T4 (da) Hydrolysering af arabinoxylan
DK2099973T3 (da) Udfoldning af gabion
DK2024504T4 (da) Fremstilling af isoprenoider
EP1967696A4 (en) TURBINE PART
DK2264042T3 (da) Mikronisering af polyoler
BRPI0807453A2 (pt) Preparação sólida
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK2700786T3 (da) Modifikation af overførselspassage
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK3255141T3 (da) Fremstilling af antistoffer med forbedret glycosyleringsmønster
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2257618T3 (da) Fremstilling af glykosylerede polypeptider i mikroalger
DK2260873T3 (da) Pcylering af proteiner
DK2125048T3 (da) Præparat
DK1879844T3 (da) Fremstilling af natriumdiformiat
DK2114147T3 (da) Reduktion af bivirkninger af tramadol
DK2081675T3 (da) Syntese af biodiesel
EP2196784A4 (en) COMBINATION SCALE
DK2083629T3 (da) Krystallinsk modifikation af fipronil
EP2053369A4 (en) COMBINATION SCALE